Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911713 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
A Phase 2 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 20
- Study locations
NCT03911713 is a Phase 2 study of Cystic Fibrosis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 77 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT03911713, a Phase 2 study of Cystic Fibrosis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IVA
- DRUG VX-561
Study Locations (20)
California
- Miller Children's Hospital / Long Beach Memorial - Long Beach
- UCSF Gateway Medical Center - San Francisco
Florida
- University of Miami Miller School of Medicine - Miami
- Central Florida Pulmonary Group, PA - Orlando
Massachusetts
- Massachusetts General Hospital Cystic Fibrosis Center Clinical Research Center - Boston
- Boston Children's Hospital - Boston
Missouri
- Cardinal Glennon Children's Hospital - St Louis
- Washington University School of Medicine / St. Louis Children's Hospital - St Louis
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Banner University of Arizona Medical Center - Tucson
Colorado
- National Jewish Health - Denver
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911713
The ClinicalTrials.gov registry entry for NCT03911713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (57% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03911713 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03911713 about?
NCT03911713 is a clinical study titled "A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis". The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.
What is the current status of trial NCT03911713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2019-04-17. Estimated completion is 2020-08-20.
What conditions does trial NCT03911713 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03911713?
The interventions under investigation include: Placebo (DRUG), IVA (DRUG), VX-561 (DRUG).
Who is sponsoring clinical trial NCT03911713?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03911713 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.